Objectives: To review the value of PSA kinetics in the diagnosis and prognosis of prostate cancer.
Methods: Review of the literature through a Medline search.
Conclusions: A pre-tretament PSAV value >2ng/ ml/yr is a risk factor for increased mortality from prostate cancer after surgery or radiation therapy. A PSADT<3ms is indicative of reduced survival after treatment. For patients with PSA recurrence after surgery a PSADT> 10 is more likely associated with local recurrence.